Clinical Trials Browser

Cholangiocarcinoma × guadecitabine × 90 days × Clear all

NCT03257761 2026-06-01

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

Phase 1 Active not recruiting

Gastrointestinal

Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Cholangiocarcinoma